THE APPLICATION OF LETERMOVIR FOR POST - HAPLOIDENTICAL TRANSPLANTATION PREVENTION IN CHILDREN WITH ACUTE LEUKEMIA DID NOT ELEVATE THE INCIDENCE OF LATE - ONSET CYTOMEGALOVIRUS INFECTION (EHA 2026) - May 12, 2026 - Abstract #EHA-6418; PB4244; "All patients received myeloablative conditioning regimens, including 21 cases based on busulfan (Bu) and 9 cases based on total body irradiation (TBI). Summary/Conclusion Letermovir prophylaxis for 100 days initiated on day +1 after haploidentical transplantation in children with acute leukemia ,led to a reduction in the incidence of CMV within 100 days after transplantation. Moreover, it did not increase the incidence of late - onset CMV from 100 days to 360 days after transplantation, nor did it reduce the disease - free survival rate after transplantation."
Clinical • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Cytomegalovirus Infection • Epstein-Barr Virus Infections • Hematological Malignancies • Infectious Disease • Leukemia • Transplantation • CD34
|